aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Tune Therapeutics, founded to harness advances in gene regulation, aims to transform human healthspan through its innovative TEMPO epigenomic control platform. The company's core mission is to redefine genetic medicine by enabling precise control over gene activity, including activation, silencing, and fine-tuning of specific genes. This technology is designed to reverse cellular dysfunction and disease, positioning Tune Therapeutics at the forefront of regenerative medicine.
Notable affiliated individuals and investors include experts with deep experience in genetic research and biotechnology. Tune Therapeutics has achieved significant milestones in developing its TEMPO platform, which has garnered attention for its potential to revolutionize therapeutic approaches. The company's impact lies in its ability to offer novel treatments that could address a wide range of genetic disorders, ultimately aiming to enhance the quality and longevity of human life.
Operating Status
Active
Ownership Type(s)
Venture Capital, Equity
Main Product(s)
Gene Therapy, Therapeutics
Technology
AI, Biotech
Model Types
Platform
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Tune Therapeutics founded?
Tune Therapeutics was founded in 2020.
Where is Tune Therapeutics’s headquarters located?
Tune Therapeutics’s headquarters is located in Seattle, US.
When was Tune Therapeutics’s last funding round?
Tune Therapeutics’s most recent funding round was for $40M (USD) in December 2021.
How many employees does Tune Therapeutics have?
Tune Therapeutics has 104 employees as of Feb 4, 2024.
How much has Tune Therapeutics raised to-date?
As of July 05, 2023, Tune Therapeutics has raised a total of $40M (USD) since Dec 2, 2021.
Add Comparison
Total Raised to Date
$40M
USD
Last Update Dec 2, 2021
Last Deal Details
$40M
USD
Dec 2, 2021
Series A
Total Employees Over Time
104
As of Feb 2024
Tune Therapeutics Address
1616 Eastlake Ave E
Seattle,
98102
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts